No Data
No Data
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades
PureTech's Cobenfy Receives FDA Approval for Schizophrenia, Unlocks $29M in Milestone Payments
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
PureTech Health Analyst Ratings
Leerink Partners Initiates Puretech Health(PRTC.US) With Buy Rating, Announces Target Price $45
No Data
No Data